Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemotherapy Based on SNF Classification in HR+/HER2- Breast Cancer
NCT06913777Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Apr 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of adebrelimab, famitinib, fluzoparib and Rivoceranib in Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative) (2 arms), sponsored by Fudan University. Primary endpoint: Pathological Complete Response Rate at 1 year. Started Apr 2025; status: recruiting.
02
Drugs
adebrelimabfamitinibfluzoparibRivoceranib
03
Conditions
Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative)
Beyond the preview
Go deeper on NCT06913777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06913777.